Login

Biomanufacturing Firm To Acquire AstraZeneca Campus in Cincinnati as Part of New Partnership

Resilience's Deal to Buy Commercial-Scale Manufacturing Plant to Close in 2023, Pending Approvals
AstraZeneca will sell its Hamilton, Ohio, campus to Resilience once the partnership is approved. (CoStar)
AstraZeneca will sell its Hamilton, Ohio, campus to Resilience once the partnership is approved. (CoStar)
By Kelly Weingart
CoStar Research
December 1, 2022 | 11:39 P.M.

Resilience is set to acquire AstraZeneca's commercial-scale drug manufacturing plant outside Cincinnati next year as part of a new long-term biomanufacturing partnership between the two companies.

This news story is available exclusively to CoStar subscribers.

Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.

This news story is available exclusively to CoStar subscribers.

Ready to Learn More?

Sign Up For a Personalized Demo.

Sign Up For a Demo To Learn More.

Already A Subscriber? Sign In